Keywords: GlaxoSmithKline, Human Genome Sciences, Benlysta, Lupus, Advisory panel, USA, FDA

GlaxoSmithKline and Human Genome fall as US FDA questions lupus drug candidate Benlysta

Article | 15 November 2010

Print This

Ahead of an advisory panel review tomorrow (November 16), the US Food and Drug Administration posted briefing documents that raise questions ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in